MET exon 14 alterations in donor and acceptor splicing sites—including point mutations, indels, and whole‐exon deletions—lead to the exclusion (skipping) of MET exon 14 at the RNA level (MET∆ex14), which has been described in 3–4% of patients with advanced NSCLC [6, 7, 8]. This evidence concerns the gene MET and non-small cell lung carcinoma.